Orchestra BioMed (OBIO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $5.45, -5.05% vs the prior close of $5.74.
- Volume 473.57K shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
OBIO slides 5.1% to $5.45, a 1-month low. Closed at $5.45, -5.05% vs the prior close of $5.74. Day range $5.37–$5.87, opened at $5.75.
OBIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — OBIO slides 5.1% to $5.45, a 1-month low
- Closed at $5.45, -5.05% vs the prior close of $5.74. Day range $5.37–$5.87, opened at $5.75.
- Volume was 473.57K shares, 1.4x its 50-day average of 333.91K.
- Price is -1.0% vs its 50-day average ($5.50) and +21.9% vs its 200-day average ($4.47).
- 52-week range $3.26–$6.50; today's close sits at 68% of that range, 16.2% below the 52-week high.
Oct 15, 2026 — OBIO rises 1.8% to $5.74
- Closed at $5.74, +1.77% vs the prior close of $5.64. Day range $5.66–$5.85, opened at $5.68.
- Volume was 253.40K shares, 0.8x its 50-day average of 331.81K.
- Price is +4.8% vs its 50-day average ($5.48) and +28.6% vs its 200-day average ($4.46).
- 52-week range $3.26–$6.50; today's close sits at 77% of that range, 11.7% below the 52-week high.
Oct 14, 2026 — OBIO dips 1.4% to $5.64, a 1-month low, 3 down days in a row
- Closed at $5.64, -1.40% vs the prior close of $5.72. Day range $5.60–$5.86, opened at $5.70.
- Volume was 222.90K shares, 0.7x its 50-day average of 330.39K.
- Price is +3.5% vs its 50-day average ($5.45) and +26.6% vs its 200-day average ($4.46).
- 52-week range $3.10–$6.50; today's close sits at 75% of that range, 13.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — OBIO slides 3.2% to $5.72
- Closed at $5.72, -3.21% vs the prior close of $5.91. Day range $5.71–$5.87, opened at $5.87.
- Volume was 204.80K shares, 0.6x its 50-day average of 330.03K.
- Price is +5.5% vs its 50-day average ($5.42) and +28.5% vs its 200-day average ($4.45).
- 52-week range $3.06–$6.50; today's close sits at 77% of that range, 12.0% below the 52-week high.
Oct 12, 2026 — OBIO dips 0.7% to $5.91
- Closed at $5.91, -0.67% vs the prior close of $5.95. Day range $5.39–$5.99, opened at $5.93.
- Volume was 237.90K shares, 0.7x its 50-day average of 328.35K.
- Price is +9.7% vs its 50-day average ($5.39) and +33.0% vs its 200-day average ($4.44).
- 52-week range $2.86–$6.50; today's close sits at 84% of that range, 9.1% below the 52-week high.
Oct 9, 2026 — OBIO jumps 3.8% to $5.95
- Closed at $5.95, +3.84% vs the prior close of $5.73. Day range $5.56–$5.97, opened at $5.73.
- Volume was 229.30K shares, 0.7x its 50-day average of 326.65K.
- Price is +11.2% vs its 50-day average ($5.35) and +34.2% vs its 200-day average ($4.44).
- 52-week range $2.78–$6.50; today's close sits at 85% of that range, 8.5% below the 52-week high.
Oct 8, 2026 — OBIO rises 1.2% to $5.73
- Closed at $5.73, +1.24% vs the prior close of $5.66. Day range $5.51–$5.83, opened at $5.75.
- Volume was 241.90K shares, 0.7x its 50-day average of 326.93K.
- Price is +7.9% vs its 50-day average ($5.31) and +29.4% vs its 200-day average ($4.43).
- 52-week range $2.66–$6.50; today's close sits at 80% of that range, 11.8% below the 52-week high.
Oct 7, 2026 — OBIO slides 3.1% to $5.66
- Closed at $5.66, -3.08% vs the prior close of $5.84. Day range $5.64–$5.86, opened at $5.79.
- Volume was 241.20K shares, 0.7x its 50-day average of 326.00K.
- Price is +7.3% vs its 50-day average ($5.27) and +28.0% vs its 200-day average ($4.42).
- 52-week range $2.66–$6.50; today's close sits at 78% of that range, 12.9% below the 52-week high.
Oct 6, 2026 — OBIO slides 3.2% to $5.84
- Closed at $5.84, -3.15% vs the prior close of $6.03. Day range $5.82–$6.12, opened at $6.05.
- Volume was 213.10K shares, 0.7x its 50-day average of 325.35K.
- Price is +11.5% vs its 50-day average ($5.24) and +32.3% vs its 200-day average ($4.41).
- 52-week range $2.66–$6.50; today's close sits at 83% of that range, 10.2% below the 52-week high.
Oct 5, 2026 — OBIO rises 1.3% to $6.03
- Closed at $6.03, +1.34% vs the prior close of $5.95. Day range $5.79–$6.09, opened at $5.89.
- Volume was 284.80K shares, 0.9x its 50-day average of 322.64K.
- Price is +16.0% vs its 50-day average ($5.20) and +36.9% vs its 200-day average ($4.41).
- 52-week range $2.66–$6.50; today's close sits at 88% of that range, 7.2% below the 52-week high.
Oct 2, 2026 — OBIO slides 6.3% to $5.95
- Closed at $5.95, -6.30% vs the prior close of $6.35. Day range $5.77–$6.44, opened at $6.40.
- Volume was 421.10K shares, 1.3x its 50-day average of 317.45K.
- Price is +15.5% vs its 50-day average ($5.15) and +35.3% vs its 200-day average ($4.40).
- 52-week range $2.50–$6.50; today's close sits at 86% of that range, 8.5% below the 52-week high.
OBIO latest news & SEC filings
Every SEC filing by or about OBIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sherman Darren sold 15,000 shares at $6.36 (≈$95.40K) on Oct 1, 2026; now holds 1,119,402
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hochman David P bought 10,000 shares at $4.79 (≈$47.90K) on Sep 3, 2026
- Hochman David P bought 10,000 shares at $4.79 (≈$47.90K) on Sep 3, 2026
- Hochman David P bought 10,000 shares at $4.79 (≈$47.90K) on Sep 3, 2026
- Hochman David P bought 10,000 shares at $4.79 (≈$47.90K) on Sep 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sherman Darren sold 15,000 shares at $4.94 (≈$74.10K) on Sep 1, 2026
- Sherman Darren sold 15,000 shares at $4.94 (≈$74.10K) on Sep 1, 2026
- Sherman Darren sold 15,000 shares at $4.94 (≈$74.10K) on Sep 1, 2026
- Sherman Darren sold 15,000 shares at $4.94 (≈$74.10K) on Sep 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $88.00K (prior year $836.00K) (-89.5% vs Jun 30, 2025)
- Net income: -$23.75M (prior year -$19.36M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.38 (prior year -$0.50) (loss narrowed vs Jun 30, 2025)
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Jun 23, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Things to know before you trade OBIO
- How much it moves: over the last 20 sessions the average daily move was 2.40% (largest 6.3%).
- Liquidity: about 281.46K shares (≈$1.53M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $5.45 vs a range of $3.26–$6.50 (68% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 12 open-market buys, 13 sales; latest: David P Hochman bought 10,000 shares on Sep 3, 2026.
- Latest filings: 8-K Oct 1, 2026; 8-K Sep 8, 2026; 10-Q Aug 10, 2026.
- Share count: 60.11M shares outstanding (Aug 6, 2026), +11.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Surgical & Medical Instruments & Apparatus.
OBIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 5.75 | 5.87 | 5.37 | 5.45 | 473.57K |
| Oct 15, 2026 | 5.68 | 5.85 | 5.66 | 5.74 | 253.40K |
| Oct 14, 2026 | 5.70 | 5.86 | 5.60 | 5.64 | 222.90K |
| Oct 13, 2026 | 5.87 | 5.87 | 5.71 | 5.72 | 204.80K |
| Oct 12, 2026 | 5.93 | 5.99 | 5.39 | 5.91 | 237.90K |
| Oct 9, 2026 | 5.73 | 5.97 | 5.56 | 5.95 | 229.30K |
| Oct 8, 2026 | 5.75 | 5.83 | 5.51 | 5.73 | 241.90K |
| Oct 7, 2026 | 5.79 | 5.86 | 5.64 | 5.66 | 241.20K |
| Oct 6, 2026 | 6.05 | 6.12 | 5.82 | 5.84 | 213.10K |
| Oct 5, 2026 | 5.89 | 6.09 | 5.79 | 6.03 | 284.80K |
| Oct 2, 2026 | 6.40 | 6.44 | 5.77 | 5.95 | 421.10K |
| Oct 1, 2026 | 6.27 | 6.50 | 6.23 | 6.35 | 389.90K |
| Sep 30, 2026 | 6.09 | 6.29 | 6.00 | 6.22 | 270.70K |
| Sep 29, 2026 | 5.89 | 6.09 | 5.83 | 6.08 | 237.10K |
| Sep 28, 2026 | 5.95 | 5.95 | 5.80 | 5.89 | 177.50K |
| Sep 25, 2026 | 5.99 | 6.17 | 5.86 | 5.95 | 248.80K |
| Sep 24, 2026 | 5.90 | 6.05 | 5.75 | 5.95 | 262.90K |
| Sep 23, 2026 | 6.10 | 6.20 | 5.90 | 5.93 | 242.30K |
| Sep 22, 2026 | 6.15 | 6.48 | 6.05 | 6.22 | 342.90K |
| Sep 21, 2026 | 6.04 | 6.29 | 5.85 | 6.25 | 433.20K |
About Orchestra BioMed
Orchestra BioMed (OBIO) is listed on the Nasdaq and classified by the SEC under “Surgical & Medical Instruments & Apparatus”. Its business address is in NEW HOPE, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1814114.
OBIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jason Aryeh | Director | Jun 25, 2026 |
| Chris Cleary | Director | Aug 14, 2026 |
| Pamela Ann Connealy | Director | Jun 25, 2026 |
| Eric S Fain | Director | Aug 14, 2026 |
| David P Hochman | See Remarks | Sep 11, 2026 |
| John Prosper Mack | Director | Aug 14, 2026 |
| David Pacitti | Director | Aug 14, 2026 |
| Darren Sherman | See Remarks | Sep 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Joshua Aiello | Principal Accounting Officer | Aug 28, 2026 |
| David P Hochman | See Remarks | Sep 11, 2026 |
| Darren Sherman | See Remarks | Sep 2, 2026 |
| Andrew Lawrence Taylor | Chief Financial Officer | Aug 28, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | David P Hochman | Buy | 10,000 | $4.79 |
| Sep 3, 2026 | David P Hochman | Buy | 10,000 | $4.79 |
| Sep 3, 2026 | David P Hochman | Buy | 10,000 | $4.79 |
| Sep 3, 2026 | David P Hochman | Buy | 10,000 | $4.79 |
| Sep 1, 2026 | Darren Sherman | Sale | 15,000 | $4.94 |
| Sep 1, 2026 | Darren Sherman | Sale | 15,000 | $4.94 |
| Sep 1, 2026 | Darren Sherman | Sale | 15,000 | $4.94 |
| Sep 1, 2026 | Darren Sherman | Sale | 15,000 | $4.94 |
| Aug 26, 2026 | Darren Sherman | Buy | 2,000 | $5.33 |
| Aug 26, 2026 | Darren Sherman | Buy | 2,000 | $5.33 |
| Aug 26, 2026 | Darren Sherman | Buy | 2,000 | $5.33 |
| Aug 26, 2026 | Darren Sherman | Buy | 2,000 | $5.33 |
| Aug 3, 2026 | Darren Sherman | Sale | 15,000 | $4.09 |
| Aug 3, 2026 | Darren Sherman | Sale | 15,000 | $4.09 |
| Aug 3, 2026 | Darren Sherman | Sale | 15,000 | $4.09 |
OBIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $33.48M | $-52.70M | -1.11 | $-48.96M |
| Dec 31, 2024 | $2.64M | $-61.02M | -1.66 | $-50.56M |
| Dec 31, 2023 | $2.76M | $-49.12M | -1.48 | $-46.13M |
| Dec 31, 2022 | $3.53M | $-33.61M | -2.24 | $-29.29M |
| Dec 31, 2021 | — | $-378.75K | -0.02 | $-272.36K |
Latest balance sheet: total assets $115.70M, total liabilities $86.28M, cash $20.47M (as of Jun 30, 2026).
OBIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Surgical & Medical Instruments & Apparatus
Boston Scientific (BSX)Stryker (SYK)3M (MMM)Dexcom (DXCM)Medline (MDLN)Becton Dickinson (BDX)MiniMed (MMED)Resmed (RMD)Insulet (PODD)West Pharmaceutical Services (WST)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on OBIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.